CSBio CSBio

X
[{"orgOrder":0,"company":"Rockwell Medical","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Rockwell Medical, Inc. Enters into Exclusive License and Supply Agreements with Sun Pharma for the Rights to Commercialize Triferic\u00ae in India","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Rockwell Medical"},{"orgOrder":0,"company":"Wanbury Limited","sponsor":"Cipla","pharmaFlowCategory":"D","amount":"$12.3 million","upfrontCash":"Undisclosed","newsHeadline":"Cipla acquires 4 key brands from Wanbury for up to Rs 89 crore.","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"February 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Wanbury Limited"},{"orgOrder":0,"company":"Fresenius Kabi AG","sponsor":"CSL Vifor","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vifor Pharma and Fresenius Kabi create joint venture in China","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"GERMANY","productType":"Small molecule","productStatus":"Approved","date":"February 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Fresenius Kabi AG"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Alnylam Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Alnylam Pharmaceuticals and Gen Sign Distribution Agreement ","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Approved","date":"March 2020","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Alnylam Pharmaceuticals"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","amount":"$400.0 million","upfrontCash":"Undisclosed","newsHeadline":"Johnson & Johnson Abandons Deal for Takeda's Tachosil Surgical Patch","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Large molecule","productStatus":"Approved","date":"April 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Takeda Pharmaceutical"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"D","amount":"$1,400.0 million","upfrontCash":"Undisclosed","newsHeadline":"Alexion Completes Acquisition of Portola","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"July 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Alexion Pharmaceuticals"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EC Clears New Class of Anaemia Therapy from Bristol Myers Squibb","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"June 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Bristol Myers Squibb"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"D","amount":"$1,400.0 million","upfrontCash":"Undisclosed","newsHeadline":"Alexion to Acquire Portola","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"May 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Alexion Pharmaceuticals"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alexion Dumps ex-Achillion C3G Program After Seeing Phase 2 Data","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"July 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Alexion Pharmaceuticals"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Corza","pharmaFlowCategory":"D","amount":"$427.0 million","upfrontCash":"427.0 million","newsHeadline":"Takeda to Divest TachoSil\u00ae to Corza Health for \u20ac350 Million","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Large molecule","productStatus":"Approved","date":"September 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Takeda Pharmaceutical"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alexion Receives CHMP Positive Opinion for New Advanced Formulation of ULTOMIRIS\u00ae (ravulizumab) with Significantly Reduced Infusion Time","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"September 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Alexion Pharmaceuticals"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vifor Pharma Announces Outcome of AFFIRM-AHF Topline Data","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"September 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"CSL Vifor"},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Glaxosmithkline's Nucala as the First and Only Biologic Treatment for Hypereosinophilic Syndrome (HES)","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"Approved","date":"September 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"GSK"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ULTOMIRIS\u00ae (ravulizumab) Receives Approval in Japan for Atypical Hemolytic Uremic Syndrome (aHUS) in Adults and Children","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"September 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Alexion Pharmaceuticals"},{"orgOrder":0,"company":"AMAG Pharmaceuticals","sponsor":"Covis Pharma","pharmaFlowCategory":"D","amount":"$647.0 million","upfrontCash":"$647.0 million","newsHeadline":"Covis Group Announces Agreement to Acquire AMAG Pharmaceuticals","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"October 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"AMAG Pharmaceuticals"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Health Canada Approves REBLOZYL\u00ae (luspatercept), New Class of Treatment for Adult Patients Living with Beta Thalassemia","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"September 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Bristol Myers Squibb"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alexion Receives FDA Approval for New Advanced Formulation of ULTOMIRIS\u00ae (ravulizumab-cwvz) with Significantly Reduced Infusion Time","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"October 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Alexion Pharmaceuticals"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alexion Announces Upcoming Data Presentations at the 62nd American Society of Hematology Annual Meeting and Exposition","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"November 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Alexion Pharmaceuticals"},{"orgOrder":0,"company":"Acceleron Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acceleron Announces REBLOZYL\u00ae Virtual Presentations at the 62nd American Society of Hematology Annual Meeting","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"November 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Acceleron Pharma"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sobi Launch Doptelet\u00ae (Avatrombopag) in Europe","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"SWEDEN","productType":"Small molecule","productStatus":"Approved","date":"November 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Swedish Orphan Biovitrum AB"},{"orgOrder":0,"company":"AMAG Pharmaceuticals","sponsor":"Covis Pharma","pharmaFlowCategory":"D","amount":"$647.0 million","upfrontCash":"$647.0 million","newsHeadline":"Covis Group Completes Acquisition of AMAG Pharmaceuticals","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"November 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"AMAG Pharmaceuticals"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"FibroGen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astellas Receives Approval of EVRENZO\u00ae in Japan for the Treatment of Anemia of Chronic Kidney Disease in Adult Patients Not on Dialysis","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"November 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Astellas Pharma"},{"orgOrder":0,"company":"Octapharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Octapharma USA Presents Research on Congenital & Acquired Bleeding Disorders at ASH Annual Meeting","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Approved","date":"December 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Octapharma"},{"orgOrder":0,"company":"Nuance Pharma","sponsor":"RTW Investments","pharmaFlowCategory":"D","amount":"$181.0 million","upfrontCash":"Undisclosed","newsHeadline":"Nuance Pharma Closes Series D Financing","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Small molecule","productStatus":"Approved","date":"December 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Nuance Pharma"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"FibroGen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Update on US Regulatory Review of Roxadustat in Anaemia of Chronic Kidney Disease","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"December 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"AstraZeneca"},{"orgOrder":0,"company":"Caplin Point Laboratories Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Caplin Point Labs Gets USFDA Nod for Anticoagulant Injection","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"January 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Caplin Point Laboratories Limited"},{"orgOrder":0,"company":"Recordati Rare Diseases","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Recordati Rare Diseases: Carbaglu\u00ae Tablets 200mg Gets Approval for A New Indication","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Recordati Rare Diseases"},{"orgOrder":0,"company":"Pharmacosmos AS","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pharmacosmos' Monoferric\u00ae (Ferric Derisomaltose) Injection is Approved by the US FDA for the Treatment of Iron Deficiency Anemia","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"DENMARK","productType":"Small molecule","productStatus":"Approved","date":"January 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Pharmacosmos AS"},{"orgOrder":0,"company":"Shield Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Australia\u2019s Therapeutic Goods Administration (TGA) Approves Feraccru\u00ae to Treat Iron Deficiency With or Without Anaemia in Adults","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"March 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Shield Therapeutics"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Approved C5 Complement Inhibitor Recommended by NICE for NHS Use","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"April 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Alexion Pharmaceuticals"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"M.D. Anderson Cancer Center","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Daiichi Sankyo's Injectafer\u00ae Receives FDA Approval for Single Dose Option for the Treatment of Adult Patients with Iron Deficiency Anemia","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"May 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Daiichi Sankyo"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apellis and Sobi Report Top-line Results from the Phase 3 PRINCE Study of EMPAVELI\u2122 (Pegcetacoplan) in Treatment-Na\u00efve Patients with PNH","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"May 2021","url1":"","url2":"","graph1":"Peptide","graph2":"Apellis Pharmaceuticals"},{"orgOrder":0,"company":"Rockwell Medical","sponsor":"Drogsan Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Rockwell Medical and Drogsan Pharmaceuticals Enter into Exclusive License Agreement for the Rights to Commercialize Triferic in Turkey","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"June 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Rockwell Medical"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"FibroGen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astellas Receives Positive CHMP Opinion for EVRENZO\u2122 (roxadustat) for Adult Patients with Symptomatic Anemia of Chronic Kidney Disease","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"June 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Astellas Pharma"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"FibroGen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astellas Receives Positive CHMP Opinion for EVRENZO\u2122 (roxadustat) for Adult Patients with Symptomatic Anemia of Chronic Kidney Disease","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"June 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Astellas Pharma"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Blueprint Medicines\u2019 Rare Blood Disease Drug Avapritinib Receives Us FDA Approval","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"June 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Blueprint Medicines"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"FibroGen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA\u2019s CRDA Committee Votes Against Approval Of AstraZeneca\u2019s Roxadustat to Treat Anaemia in Chronic Kidney Disease","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"July 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"AstraZeneca"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Seeks More Trial Data on Astrazeneca\u2019s NDA for Roxadustat for CKD","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"August 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"AstraZeneca"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"FibroGen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astellas Receives EC Approval for First-in-Class EVRENZO for Adult Patients with Symptomatic Anemia of Chronic Kidney Disease","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"August 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Astellas Pharma"},{"orgOrder":0,"company":"FibroGen","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astellas Receives EC Approval for First-in-Class EVRENZO for Adult Patients with Symptomatic Anemia of Chronic Kidney Disease","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"August 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"FibroGen"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca\u2019s Ultomiris Approved for Use on Children in EU","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"Approved","date":"September 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"AstraZeneca"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apellis and Sobi Receive Positive CHMP Opinion for Aspaveli\u00ae (Pegcetacoplan) for the Treatment of PNH","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"October 2021","url1":"","url2":"","graph1":"Peptide","graph2":"Apellis Pharmaceuticals"},{"orgOrder":0,"company":"GSK","sponsor":"","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GSK Announces Positive Phase III Efficacy and Safety Data for Daprodustat in Patients with Anaemia Due to Chronic Kidney Disease","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"November 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"GSK"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"CSL","pharmaFlowCategory":"D","amount":"$11,700.0 million","upfrontCash":"$11,700.0 million","newsHeadline":"CSL Limited Announces Tender Offer to Acquire Vifor Pharma Ltd","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"December 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"CSL Vifor"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nature Medicine Publishes Results from Two Registration Studies of AYVAKIT\u00ae (Avapritinib) Showing Sustained Benefits in Patients with Advanced Systemic Mastocytosis","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"December 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Blueprint Medicines"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aspaveli\u00ae\/Empaveli\u2122 (Pegcetacoplan) Demonstrated Sustained Normalisation of Clinical Measures in a Broad PNH Patient Population","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"December 2021","url1":"","url2":"","graph1":"Peptide","graph2":"Apellis Pharmaceuticals"},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Medicines Agency (EMA) Accepts Marketing Authorisation Application for Daprodustat","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"March 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"GSK"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ondexxya Approved in Japan for Reversal of Acute Major Bleeds in Patients on Factor Xa Inhibitors","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"Approved","date":"March 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"AstraZeneca"},{"orgOrder":0,"company":"Bio Products Laboratory","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BPL Receives Orphan Drug Marketing Authorization for Coagadex\u00ae in Mexico","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"Approved","date":"May 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Bio Products Laboratory"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apellis Announces Seven Abstracts in PNH to be Presented at the European Hematology Association Congress","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"May 2022","url1":"","url2":"","graph1":"Peptide","graph2":"Apellis Pharmaceuticals"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus to Launch OxemiaTM (Desidustat) a Breakthrough Treatment for Anemia in Patients Suffering From Chronic Kidney Disease (CKD)","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"March 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Zydus Lifesciences"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astellas Analysis Shows No Evidence of Increased Risk of Cardiovascular Events or Mortality with Roxadustat Compared with Erythropoiesis-Stimulating Agents (ESAs) at 59th ERA Congress 2022","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"May 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Astellas Pharma"},{"orgOrder":0,"company":"Aucta Pharmaceuticals","sponsor":"Oakrum Pharma, LLC","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oakrum Pharma and Aucta Pharma Announce U.S. FDA Approval of Generic Version of JADENU\u00ae Sprinkle (Deferasirox Granules)","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Aucta Pharmaceuticals"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Kashiv BioSciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amneal Achieves Third U.S. Biosimilar Approval with FYLNETRA\u2122 (pegfilgrastim-pbbk)","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Large molecule","productStatus":"Biosimilar","date":"May 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Amneal Pharmaceuticals"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apellis and Sobi Report New Data Reinforcing the Robust Efficacy and Safety Profile of EMPAVELI (pegcetacoplan) for PNH at EHA 2022 Congress","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"June 2022","url1":"","url2":"","graph1":"Peptide","graph2":"Apellis Pharmaceuticals"},{"orgOrder":0,"company":"Danone","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Infant Formula Update: June 17, 2022","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"June 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Danone"},{"orgOrder":0,"company":"Kashiv BioSciences","sponsor":"Brand Institute","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Brand Institute Partners on Brand Name Development for FDA Approved Treatment for Febrile Neutropenia in Cancer Patients","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Large molecule","productStatus":"Biosimilar","date":"June 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Kashiv BioSciences"},{"orgOrder":0,"company":"Spherix Global Insights","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Nephrologists Lead the Way with Adoption of Astellas\/FibroGen\u2019s HIF-PH inhibitor, EVRENZO (roxadustat), for Anemia of CKD Treatment in Both Dialysis and Non-Dialysis Settings","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"June 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Spherix Global Insights"},{"orgOrder":0,"company":"American Regent","sponsor":"Provepharm Life Solutions","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"American Regent Launches a New Vial Presentation","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"June 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"American Regent"},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fresenius Kabi Receives European Commission Approval for its Pegfilgrastim Biosimilar Stimufend\u00ae - Fresenius Kabi Global","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"SWEDEN","productType":"Large molecule","productStatus":"Biosimilar","date":"March 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Fresenius Kabi AB Brunna"},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GSK Announces Update on US FDA Regulatory Review of Daprodustat in Anaemia of Chronic Kidney Disease","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"September 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"GSK"},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fresenius Kabi Receives U.S. FDA Approval for Biosimilar Stimufend\u00ae (pegfilgrastim-fpgk)","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"SWEDEN","productType":"Large molecule","productStatus":"Biosimilar","date":"September 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Fresenius Kabi AB Brunna"},{"orgOrder":0,"company":"Pharmacosmos AS","sponsor":"Zydus Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Zydus Buys Rights from Pharmacosmos to Sell Drug to Treat Anemia in India, Nepal","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"DENMARK","productType":"Small molecule","productStatus":"Approved","date":"September 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Pharmacosmos AS"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spectrum Pharmaceuticals Receives FDA Approval for ROLVEDON\u2122 (eflapegrastim-xnst) Injection","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"September 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Spectrum Pharmaceuticals"},{"orgOrder":0,"company":"JSR Life Sciences","sponsor":"Blau Farmaceutica","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Similis Bio Partners With Blau Farmaceutica to Co-Develop Four Biosimilar Programs","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Large molecule","productStatus":"Biosimilar","date":"October 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"JSR Life Sciences"},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GSK Reports Outcome From US FDA Advisory Committee Meeting On Daprodustat For Anaemia Of CKD","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"October 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"GSK"},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GSK Reports Outcome From US FDA Advisory Committee Meeting on Daprodustat for Anaemia of CKD","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"October 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"GSK"},{"orgOrder":0,"company":"FibroGen","sponsor":"NovaQuest Capital Management","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"$50.0 million","newsHeadline":"FibroGen Announces $50 Million Royalty Monetization Financing with NovaQuest Capital Management","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"November 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"FibroGen"},{"orgOrder":0,"company":"Dong-A ST Co., Ltd.","sponsor":"Polifarma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Dong-A ST Signs License-out Deal with Polifarma of T\u00fcrkiye for NESP\u00ae Biosimilar DA-3880","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"Biosimilar","date":"November 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Dong-A ST Co., Ltd."},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PYRUKYND\u00ae (mitapivat) Approved in the EU for the Treatment of Pyruvate Kinase (PK) Deficiency in Adult Patients","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"November 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Agios Pharmaceuticals"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amneal Launches Second Biosimilar with RELEUKO\u00ae (filgrastim-ayow) in the United States","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Large molecule","productStatus":"Biosimilar","date":"November 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Amneal Pharmaceuticals"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ferinject\u00ae Approved In Chinafor The Treatment Of Iron Deficiency In Adult Patients","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"November 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"CSL Vifor"},{"orgOrder":0,"company":"Kashiv BioSciences","sponsor":"Amneal Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kashiv Biosciences Achieves Second U.S. Biosimilar Approval with FYLNETRA\u00ae (pegfilgrastim-pbbk)","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"May 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Kashiv BioSciences"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spectrum Pharmaceuticals Provides Update on Rolvedon\u2122 (eflapegrastim-xnst) Injection and Announces Unaudited Fourth Quarter 2022 Financial Results","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"January 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Spectrum Pharmaceuticals"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$5,400.0 million","upfrontCash":"$5,400.0 million","newsHeadline":"Pfizer to Acquire Global Blood Therapeutics for $5.4 Billion to Enhance Presence in Rare Hematology","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"August 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Global Blood Therapeutics"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves UDENYCA\u00ae Autoinjector","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Large molecule","productStatus":"Biosimilar","date":"March 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Coherus Biosciences"},{"orgOrder":0,"company":"BIOSYENT PHARMA INC","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioSyent Announces Launch of New FeraMAX Pd Maintenance 45","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"March 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"BIOSYENT PHARMA INC"},{"orgOrder":0,"company":"Endo International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Endo Announces Launch of Argatroban Injection Through Premier's ProRx\u00ae Private-Label Program","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"IRELAND","productType":"Small molecule","productStatus":"Approved","date":"April 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Endo International"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Assertio Therapeutics","pharmaFlowCategory":"D","amount":"$757.0 million","upfrontCash":"$291.0 million","newsHeadline":"Assertio Holdings, Inc. to Acquire Spectrum Pharmaceuticals, Inc. in All Stock and CVR Transaction","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"April 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Spectrum Pharmaceuticals"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akebia Receives European Commission Approval for Vafseo\u2122 (vadadustat) for the Treatment of Symptomatic Anaemia Associated with Chronic Kidney Disease in Adults on Chronic Maintenance Dialysis","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Akebia Therapeutics"},{"orgOrder":0,"company":"FibroGen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FibroGen Announces Results for MATTERHORN, a Phase 3 Clinical Study of Roxadustat for the Treatment of Anemia in Patients with Myelodysplastic Syndromes (MDS)","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"May 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"FibroGen"},{"orgOrder":0,"company":"Microbix Biosystems","sponsor":"Sequel Pharma","pharmaFlowCategory":"D","amount":"$35.0 million","upfrontCash":"Undisclosed","newsHeadline":"Microbix Secures Funded Drug Commercialization Agreement","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Large molecule","productStatus":"Approved","date":"May 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Microbix Biosystems"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Kashiv BioSciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amneal Launches Third Biosimilar with FYLNETRA\u2122 (pegfilgrastim-pbbk) in the United States","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Large molecule","productStatus":"Biosimilar","date":"May 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Amneal Pharmaceuticals"},{"orgOrder":0,"company":"Lobe Sciences","sponsor":"Pentec Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lobe Sciences Announces Commercial Distribution Agreement With Pentec Health for US Launch of Altemia\u2122","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"May 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Lobe Sciences"},{"orgOrder":0,"company":"Emcure Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Emcure Pharmaceuticals to Launch The 750 Mg Injectable Variant of Ferric Carboxymaltose","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"May 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Emcure Pharmaceuticals"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Coherus Announces U.S. Launch of UDENYCA Autoinjector","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Large molecule","productStatus":"Biosimilar","date":"May 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Coherus Biosciences"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akebia Announces UK MHRA Approval of Vafseo\u00ae (vadadustat) for the Treatment of Symptomatic Anemia Associated with Chronic Kidney Disease in Adults on Chronic Maintenance Dialysis","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"May 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Akebia Therapeutics"},{"orgOrder":0,"company":"Endo International","sponsor":"MAIA Biotechnology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Endo Announces Agreement with MAIA Pharmaceuticals to Distribute Bivalirudin Injection in Ready-to-Use Vials","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"IRELAND","productType":"Peptide","productStatus":"Approved","date":"May 2023","url1":"","url2":"","graph1":"Peptide","graph2":"Endo International"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CHMP Recommends Revoking the Conditional Marketing Authorization for Adakveo\u00ae (crizanlizumab)","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Approved","date":"May 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Provides Akebia Therapeutics a Path Forward for Vadadustat","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"May 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Akebia Therapeutics"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"American Regent","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"INJECTAFER Approved in the U.S. for the Treatment of Iron Deficiency in Adult Patients with Heart Failure","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"June 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Daiichi Sankyo"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"CSL","pharmaFlowCategory":"D","amount":"$11,700.0 million","upfrontCash":"$11,700.0 million","newsHeadline":"Finalization of Vifor Pharma Acquisition","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"August 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"CSL Vifor"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akebia Announces Swissmedic Approval of Vafseo (vadadustat)","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"June 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Akebia Therapeutics"},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GSK Receives Positive CHMP Opinion Recommending Authorisation of Daprodustat for Symptomatic Anaemia Associated with Chronic Kidney Disease in Adults on Chronic Maintenance Dialysis","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"June 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"GSK"},{"orgOrder":0,"company":"Nemysis","sponsor":"Bruno Farmaceutici","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nemysis Limited Signs IHAT Sales and Marketing Agreement","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"IRELAND","productType":"Small molecule","productStatus":"Approved","date":"July 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Nemysis"},{"orgOrder":0,"company":"Endo International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Endo Launches Bivalirudin Injection in Ready-to-Use Vials","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"IRELAND","productType":"Peptide","productStatus":"Approved","date":"July 2023","url1":"","url2":"","graph1":"Peptide","graph2":"Endo International"},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Emmaus Life Sciences Receives Marketing Authorization for Endari in Oman","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"July 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Emmaus Life Sciences"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Commission (EC) Adopts Decision Endorsing CHMP Recommendation to Revoke the Conditional Marketing Authorization for Adakveo\u00ae (crizanlizumab)","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Approved","date":"August 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"American Regent","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"American Regent Announces Results From Phase 3 HEART-FID Trial with INJECTAFER\u00ae","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"August 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"American Regent"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akebia Therapeutics Expects to Resubmit Vadadustat NDA in Third Quarter 2023","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"August 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Akebia Therapeutics"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ferinject\u00ae Granted Upgraded Recommendations in 2023 ESC Heart Failure Guidelines","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"August 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"CSL Vifor"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Issues Complete Response Letter (CRL) for UDENYCA\u00ae ONBODY\u201e\u00a2 Biologics License Application Solely Due to an Ongoing Review of Inspection Findings at a Third-Party Filler; Coherus Also Announces Completion of Toripalimab FDA Inspections","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Large molecule","productStatus":"Biosimilar","date":"September 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Coherus Biosciences"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akebia Announces Approval of Vafseo (vadadustat) in Australia and Provides Commercial Update","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"September 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Akebia Therapeutics"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sun Pharma and Zydus Sign Licensing Agreement for Co-Marketing of Desidustat, a Critical Treatment Option for Chronic Kidney Disease Patients in India","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"October 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Zydus Lifesciences"},{"orgOrder":0,"company":"SHENZHEN SALUBRIS PHARMACEUTICALS CO.LTD.","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enarodustat (ONNARO\u00ae) Approved by NMPA for Treatment of Renal Anemia (Abstract) NMPA approved Enarodustat (ONNARO\u00ae)","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Small molecule","productStatus":"Approved","date":"June 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"SHENZHEN SALUBRIS PHARMACEUTICALS CO.LTD."},{"orgOrder":0,"company":"RoslinCT","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Roslinct to Manufacture Exagamglogene Autotemcel (Exa-cel) for Vertex Pharmaceuticals Inc Following an Extensive Development Collaboration","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"Approved","date":"November 2023","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"RoslinCT"},{"orgOrder":0,"company":"Minapharm Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sanofi and Minapharm Sign an Exclusive Agreement for Localizing the Manufacture of Clexane\u00ae","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"EGYPT","productType":"Small molecule","productStatus":"Approved","date":"December 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Minapharm Pharmaceuticals"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Editas Medicine and Vertex Pharmaceuticals Enter into Non-exclusive License Agreement for Cas9","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Approved","date":"December 2023","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Editas Medicine"},{"orgOrder":0,"company":"Charles River Laboratories, Inc","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Charles River and Vertex Pharmaceuticals Reach Important Milestone in Cell Therapy Manufacturing Collaboration","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Approved","date":"December 2023","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Charles River Laboratories, Inc"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vertex Announces Approval of First CRISPR\/Cas9 Gene-Edited Therapy, CASGEVY\u2122, for the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT) in Kingdom of Saudi Arabia","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Approved","date":"January 2024","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Vertex Pharmaceuticals"},{"orgOrder":0,"company":"Kolinpharma","sponsor":"Nemysis","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nemysis Limited Signs with Kolinpharma SpA an IHAT Sales and Marketing Agreement","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"ITALY","productType":"Small molecule","productStatus":"Approved","date":"January 2024","url1":"","url2":"","graph1":"Small molecule","graph2":"Kolinpharma"},{"orgOrder":0,"company":"Avenacy","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avenacy Announces Launch of Bivalirudin for Injection in the U.S. Market","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"January 2024","url1":"","url2":"","graph1":"Peptide","graph2":"Avenacy"}]

Find Approved Hematology Drugs in Clinical Development

Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Product Type
          filter News Type

            Active Filter(s):

            Product Type

            Companies

            Details:

            JADENU (deferasirox) tablets for oral use and JADENU® Sprinkle (deferasirox) granules are indicated for the treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age and older.

            Lead Product(s): Deferasirox

            Therapeutic Area: Hematology Product Name: Jadenu

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Oakrum Pharma, LLC

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 22, 2021

            Details:

            Angiomax-Generic (bivalirudin) is a direct thrombin inhibitor, which is now launched in the US market. It is indicated for treatment of patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome.

            Lead Product(s): Bivalirudin

            Therapeutic Area: Hematology Product Name: Angiomax-Generic

            Highest Development Status: Approved Product Type: Peptide

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 29, 2024

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the agreement, Kolinpharma will use its existing sales network and relationships with relevant clinical communities to market Iron Hydroxide Adipate Tartrate (IHAT), an oral iron supplementation product for iron deficiency, under its brand KIPFeR.

            Lead Product(s): Iron Hydroxide Adipate Tartrate

            Therapeutic Area: Hematology Product Name: KIPFeR

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Nemysis

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement January 10, 2024

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Casgevy (exagamglogene autotemcel) is an investigational, autologous, ex vivo CRISPR/Cas9 gene-edited therapy that is indicated for patients with Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia.

            Lead Product(s): Exagamglogene Autotemcel

            Therapeutic Area: Hematology Product Name: Casgevy

            Highest Development Status: Approved Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 09, 2024

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the agreement, Charles River will manufacture Vertex’s CASGEVY (exagamglogene autotemcel) therapy, the world’s first gene-edited therapy targeting severe sickle cell disease.

            Lead Product(s): Exagamglogene Autotemcel

            Therapeutic Area: Hematology Product Name: Casgevy

            Highest Development Status: Approved Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Vertex Pharmaceuticals

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration December 18, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Vertex will obtain a non-exclusive license for Editas Medicine’s Cas9 gene editing technology for ex vivo gene editing medicines targeting the BCL11A gene in the fields of sickle cell disease and beta thalassemia, including Casgevy (exagamglogene autotemcel).

            Lead Product(s): Exagamglogene Autotemcel

            Therapeutic Area: Hematology Product Name: Casgevy

            Highest Development Status: Approved Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Vertex Pharmaceuticals

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement December 13, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The agreement aims for the for the localization of the full range of its flagship market leader product, Clexane (enoxaparin sodium), used to prevent clots from getting bigger or stopping new clots from forming.

            Lead Product(s): Enoxaparin Sodium

            Therapeutic Area: Hematology Product Name: Clexane

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Sanofi

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement December 10, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the collaboration, RoslinCT will manufacture the world’s first CRISPR-based therapy, exa-cel (exagamglogene autotemcel), a new treatment for sickle cell disease and transfusion-dependent beta thalassemia, across the world for Vertex.

            Lead Product(s): Exagamglogene Autotemcel

            Therapeutic Area: Hematology Product Name: Exa-cel

            Highest Development Status: Approved Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Vertex Pharmaceuticals

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration November 28, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the terms of this agreement, Zydus has granted Sun Pharma semi-exclusive rights to comarket an innovative drug, Rytstat (desidustat), first-of-its-kind oral treatment for anemia associated with Chronic Kidney Disease, in India.

            Lead Product(s): Desidustat

            Therapeutic Area: Hematology Product Name: Rytstat

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Sun Pharmaceutical Industries Limited

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement October 30, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Vafseo (vadadustat) is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor designed to mimic the physiologic effect of altitude on oxygen availability. Vadadustat is currently approved for use in 34 countries.

            Lead Product(s): Vadadustat

            Therapeutic Area: Hematology Product Name: Vafseo

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 26, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY